Angion Biomedica Corp ANGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:05 PM EDT
1.07quote price arrow down-0.02 (-1.83%)
Volume
38,629
52 week range
0.98 - 14.18
Loading...
  • Open1.13
  • Day High1.14
  • Day Low1.05
  • Prev Close1.09
  • 52 Week High14.18
  • 52 Week High Date08/11/21
  • 52 Week Low0.98
  • 52 Week Low Date07/25/22

Key Stats

  • Market Cap32.06M
  • Shares Out29.96M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-63.79

KEY STATS

  • Open1.13
  • Day High1.14
  • Day Low1.05
  • Prev Close1.09
  • 52 Week High14.18
  • 52 Week High Date08/11/21
  • 52 Week Low0.98
  • 52 Week Low Date07/25/22
  • Market Cap32.06M
  • Shares Out29.96M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-63.79

RATIOS/PROFITABILITY

  • EPS (TTM)-1.08
  • P/E (TTM)-0.99
  • Fwd P/E (NTM)-0.55
  • EBITDA (TTM)-33.727M
  • ROE (TTM)-40.25%
  • Revenue (TTM)29.59M
  • Gross Margin (TTM)92.97%
  • Net Margin (TTM)-108.57%
  • Debt To Equity (MRQ)0.42%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Angion Biomedica Corp

There is no recent news for this security.

Profile

MORE
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company’s products include ANG-3070, ROCK2 Inhibitor, CYP11B2 Inhibitor and ANG-3777. ANG-3070 is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung....
Jay Venkatesan M.D.
Chairman of the Board, President, Chief Executive Officer
Itzhak Goldberg M.D.
Chairman Emeritus, Director
Gregory Curhan
Chief Financial Officer
Jennifer Rhodes J.D.
Executive Vice President, Chief Business Officer, Chief Compliance Officer, General Counsel, Corporate Secretary
John Neylan M.D.
Executive Vice President, Chief Medical Officer, Head of Research
Address
51 Charles Lindbergh Boulevard
Uniondale, NY
11553
United States

Top Peers

SYMBOLLASTCHG%CHG
BTX
Brooklyn Immunotherapeutics Inc
0.5052-0.0232-4.3906%
ORGS
Orgenesis Inc
1.83+0.05+2.81%
OBSV
Obseva SA
0.28-0.0021-0.7444%
CDAK
Codiak BioSciences, Inc.
2.42+0.03+1.26%
SYRS
Syros Pharmaceuticals Inc
0.9002+0.0002+0.02%